Stifel lowers Biogen (NASDAQ:BIIB) price target from $324 to $320

By / / Biogen, Stifel

Stifel analyst Paul Matteis maintains Biogen (NASDAQ:BIIB) with a Buy and lowers the price target from $324 to $320.

Scroll to Top